Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Boceprevir in Genotype 1 Hepatitis C (SPRINT-1)
NCT00423670Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2007
- Primary completion
- Aug 2008
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, open-label trial of boceprevir in hepatitis C (HCV) (8 arms), sponsored by Merck & Co. Primary endpoint: Sustained Virologic Response. Started Jan 2007; status: completed.
02
Drugs
boceprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00423670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423670.